- New shorter duration of dual anti-platelet therapy (DAPT) post XIENCE stent implant provides physicians with additional options to treat patients at high risk of bleeding - XIENCE is the most used ...
- XIENCE stents have 10+ years of clinical data across 120 clinical trials, more than 125,000 patients and 15 million stent¹ implants ABBOTT PARK, Ill., June 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ...
A clinical study has shown Abbott Laboratories' "Xience," a drug-coated stent, to be more effective than Boston Scientific's Taxus device. This result clears Abbott to seek FDA approval for the Xience ...
Supported by Data from the SPIRIT Family of Clinical Trials, Which Demonstrated Strong Safety and Efficacy for XIENCE V® Available in a Broad Size Matrix, XIENCE PRIME is the Only Everolimus Eluting ...
Government health advisers are scheduled to vote Thursday on whether Abbott Laboratories' drug-coated stent Xience should be approved for use in the U.S. The Food and Drug Administration is expected ...
Abbott (NYSE: ABT) announced today positive one-year clinical results from ABSORB Japan, a multi-center, randomized trial comparing the safety and effectiveness of Abbott's fully dissolving Absorb™ ...
Abbott Park, Illinois (NYSE: ABT) - Abbott today announced that the U.S. Food and Drug Administration (FDA) approved the XIENCE TM V Everolimus Eluting Coronary Stent System for the treatment of ...
Abbott today announced its XIENCE stent has received CE Mark in Europe for shorter duration of dual antiplatelet therapy (DAPT) – as short as 28 days, the shortest indication available in the world – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results